Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michelle Crank

Allergy & Immunology Wheaton, MD Medical Doctor

NPI 1861601650 CMS profile 7225616

11002 Veirs Mill Rd Ste 414, Wheaton, MD 20902

Open in the dashboard

General payments

$10,794

477 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,000 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Michelle Crank of Wheaton, MD is reported in the CMS Open Payments database as having received $10,794 across 477 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 73rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,980 80
2024 General $2,186 92
2023 General $1,854 91
2022 General $1,508 73
2021 General $1,671 80
2020 General $1,515 57
2019 General $80 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Crank
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Michelle Crank were reported at $1,980. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Michelle Crank Allergy & Immunology median Middle half National median
2019 $80 $594 $163–$1,512 $163
2020 $1,515 $426 $106–$1,233 $114
2021 $1,671 $638 $157–$1,708 $132
2022 $1,508 $790 $205–$1,961 $149
2023 $1,854 $852 $220–$2,147 $160
2024 $2,186 $865 $203–$2,267 $164
2025 $1,980 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,071 51 payments
  2. AstraZeneca Pharmaceuticals LP $983 52 payments
  3. Octapharma USA, Inc. $930 18 payments
  4. BioCryst US Sales Co., LLC $804 44 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $759 31 payments
  6. CSL Behring $667 29 payments
  7. Pfizer Inc. $622 38 payments
  8. Novartis Pharmaceuticals Corporation $542 23 payments
  9. Regeneron Healthcare Solutions, Inc. $541 22 payments
  10. Genzyme Corporation $479 15 payments
  11. Other $3,396 154 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,703 473 payments
  2. Consulting Fee $66 3 payments
  3. Education $25 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT $809 27 payments
  2. Orladeyo $804 44 payments
  3. CUTAQUIG Immunology $699 10 payments
  4. NUCALA $594 26 payments
  5. Hizentra $575 25 payments
  6. CUVITRU $528 23 payments
  7. CUTAQUIG Immunology $451 29 payments
  8. TEZSPIRE $434 18 payments
  9. Xhance $402 18 payments
  10. PANZYGA $393 26 payments
  11. Other $6,612 322 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

262

Median for Allergy/ Immunology: 449

Drug cost

$38,495

Median for Allergy/ Immunology: $169,700

Branded share of claims

55.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $20,386
Advair Hfa Fluticasone Propion/Salmeterol Brand 12 $3,861
Wixela Inhub Fluticasone Propion/Salmeterol Brand 23 $3,553
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 17 $3,408
Azelastine-Fluticasone Azelastine/Fluticasone Brand 16 $3,062
Albuterol Sulfate Hfa Albuterol Sulfate Brand 50 $1,234
Azelastine Hcl Generic 12 $708
Fluticasone Propionate Generic 20 $689
Ipratropium Bromide Generic 24 $593
Montelukast Sodium Generic 30 $569

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$638,244

Of which drugs: $504,364

Medicare patients

317

Average age 73

Services billed

21,899

232 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 54%
Osteoporosis 26%
Diabetes 19%
Depression 18%
Ischemic heart disease 17%
COPD 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin (bivigam), 500 mg J1556 Office 13 3,690 $214,516
Injection, omalizumab, 5 mg J2357 Office 20 4,740 $142,243

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $224
  • GENZYME CORPORATION $73
$297 — —
TEZSPIRE
  • Amgen Inc. $138
  • AstraZeneca Pharmaceuticals LP $102
$240 — —
Orladeyo
  • BioCryst US Sales Co., LLC $233
$233 — —
NUCALA
  • GlaxoSmithKline, LLC. $218
$218 — —
TAKHZYRO
  • Takeda Pharmaceuticals U.S.A., Inc. $169
$169 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

477 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record